Birmingham-based pharmaceutical company Henderson Morley (HML) saw its shares increase more than five per cent after continued interest in its new products.
The company, based in Moseley, is in talks with a number of animal health companies regarding further development of a fish vaccine adjuvant.
Shares closed up 5.5 per cent at 0.48p, an increase of 0.03p.
The company has started trials examining the role of a proprietary vaccine adjuvant, designed for use in the Koi herpes virus vaccine programme, and possible use in other commercially important fish vaccines.
Koi carp are extremely valuable fish, with prime breeding stock fetching tens of thousands of pounds each.
Adjuvants are non-specific stimulators that ‘kick start’ the immune system, usually given simultaneously with a vaccine, and ideally have no adverse effects.
